A. K. Rosenthal, J. K. Mclaughlin, G. Gridley, and O. Nyrén, Incidence of cancer among patients with systemic sclerosis, Cancer, vol.76, issue.5, pp.910-914, 1995.

C. Hill, A. Nguyen, and D. Roder, Risk of cancer in patients with scleroderma: a population based cohort study, Annals of the Rheumatic Diseases, vol.62, issue.8, pp.728-731, 2003.

, Annals of the Rheumatic Diseases, Ann Rheum Dis, vol.62, pp.728-759

S. Chatterjee, G. W. Dombi, R. K. Severson, and M. D. Mayes, Risk of malignancy in scleroderma: A population-based cohort study, Arthritis & Rheumatism, vol.52, issue.8, pp.2415-2424, 2005.

C. T. Derk, C. M. Artlett, and S. A. Jimenez, Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study, Clinical Rheumatology, vol.25, issue.6, pp.831-834, 2006.

K. Y. Kang, H. W. Yim, I. Kim, J. U. Yoon, J. H. Ju et al., Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre, Scandinavian Journal of Rheumatology, vol.38, issue.4, pp.299-303, 2009.

A. B. Olesen, C. Svaerke, D. K. Farkas, and H. T. Sørensen, Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study, British Journal of Dermatology, vol.163, issue.4, pp.800-806, 2010.

C. Kuo, S. Luo, K. Yu, I. Chou, W. Tseng et al., Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan, Scandinavian Journal of Rheumatology, vol.41, issue.1, pp.44-49, 2011.

A. Hashimoto, Y. Arinuma, T. Nagai, S. Tanaka, T. Matsui et al., Incidence and the Risk Factor of Malignancy in Japanese Patients with Systemic Sclerosis, Internal Medicine, vol.51, issue.13, pp.1683-1688, 2012.

A. Onishi, D. Sugiyama, S. Kumagai, and A. Morinobu, Cancer Incidence in Systemic Sclerosis: Meta-Analysis of Population-Based Cohort Studies, Arthritis & Rheumatism, vol.65, issue.7, pp.1913-1921, 2013.

M. Bonifazi, I. Tramacere, G. Pomponio, B. Gabrielli, E. V. Avvedimento et al., Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies, Rheumatology, vol.52, issue.1, pp.143-154, 2012.

J. Zhang, Y. Wan, W. Peng, J. Yan, B. Li et al., The risk of cancer development in systemic sclerosis: A meta-analysis, Cancer Epidemiology, vol.37, issue.5, pp.523-527, 2013.

T. Igusa, L. K. Hummers, K. Visvanathan, C. Richardson, F. M. Wigley et al., Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer, Annals of the Rheumatic Diseases, vol.77, p.annrheumdis-2018-212999, 2018.

A. A. Shah and L. Casciola-rosen, Cancer and scleroderma, Current Opinion in Rheumatology, vol.27, issue.6, pp.563-570, 2015.

P. Airo?, A. Ceribelli, I. Cavazzana, M. Taraborelli, S. Zingarelli et al., Malignancies in Italian Patients with Systemic Sclerosis Positive for Anti-RNA Polymerase III Antibodies, The Journal of Rheumatology, vol.38, issue.7, pp.1329-1334, 2011.

M. Nikpour, P. Hissaria, J. Byron, J. Sahhar, M. Micallef et al., Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort, Arthritis Research & Therapy, vol.13, issue.6, p.R211, 2011.

P. Moinzadeh, C. Fonseca, M. Hellmich, A. A. Shah, C. Chighizola et al., Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma, Arthritis Research & Therapy, vol.16, issue.1, p.R53, 2014.

A. A. Shah, A. Rosen, L. Hummers, F. Wigley, and L. Casciola-rosen, Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies, Arthritis & Rheumatism, vol.62, issue.9, pp.2787-2795, 2010.

C. G. Joseph, E. Darrah, A. A. Shah, A. D. Skora, L. A. Casciola-rosen et al., Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer, Science, vol.343, issue.6167, pp.152-157, 2013.

M. Dolcino, A. Pelosi, P. F. Fiore, G. Patuzzo, E. Tinazzi et al., Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures, Frontiers in Immunology, vol.9, 2018.

M. Dolcino, A. Pelosi, P. F. Fiore, G. Patuzzo, E. Tinazzi et al., Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures, Frontiers in Immunology, vol.9, p.449, 2018.

M. Pesic and F. R. Greten, Inflammation and cancer: tissue regeneration gone awry, Current Opinion in Cell Biology, vol.43, pp.55-61, 2016.

L. B. Travis, R. E. Curtis, B. Glimelius, E. J. Holowaty, F. E. Van-leeuwen et al., Bladder and Kidney Cancer Following Cyclophosphamide Therapy for Non-Hodgkin's Lymphoma, JNCI Journal of the National Cancer Institute, vol.87, issue.7, pp.524-531, 1995.

C. Talar-williams, Y. M. Hijazi, and M. M. Walther, Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis, Annals of Internal Medicine, vol.124, issue.5, p.477, 1996.

A. Gulamhusein and J. E. Pope, Squamous Cell Carcinomas in 2 Patients with Diffuse Scleroderma Treated with Mycophenolate Mofetil, The Journal of Rheumatology, vol.36, issue.2, pp.460-461, 2009.

C. C. Berger, C. Bokemeyer, M. Schneider, M. A. Kuczyk, and H. Schmoll, Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer, European Journal of Cancer, vol.31, issue.13-14, pp.2229-2238, 1995.

T. Shimura, N. Fuse, T. Yoshino, K. Minashi, M. Tahara et al., Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer, Annals of Oncology, vol.21, issue.10, pp.2005-2010, 2010.

B. Park, R. C. Vemulapalli, A. Gupta, M. E. Shreve, and D. A. Rees, Docetaxel-Induced Systemic Sclerosis with Internal Organ Involvement Masquerading as Congestive Heart Failure, Case Reports in Immunology, vol.2017, pp.1-3, 2017.

A. Moeller, K. Ask, D. Warburton, J. Gauldie, and M. Kolb, The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?, The International Journal of Biochemistry & Cell Biology, vol.40, issue.3, pp.362-382, 2008.

A. T. Maria, L. Partouche, R. Goulabchand, S. Rivière, P. Rozier et al., Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors, Frontiers in Immunology, vol.9, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02307243

A. A. Shah, L. Casciola?rosen, and A. Rosen, Review: Cancer?Induced Autoimmunity in the Rheumatic Diseases, Arthritis & Rheumatology, vol.67, issue.2, pp.317-326, 2015.

A. J. Tyndall, B. Bannert, M. Vonk, P. Airo, F. Cozzi et al., Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database, Annals of the Rheumatic Diseases, vol.69, issue.10, pp.1809-1815, 2010.

M. Elhai, C. Meune, M. Boubaya, J. Avouac, E. Hachulla et al., Mapping and predicting mortality from systemic sclerosis, Annals of the Rheumatic Diseases, vol.76, issue.11, pp.1897-1905, 2017.

E. C. Leroy, C. Black, and R. Fleischmajer, Pathogenesis of Scleroderma (Systemic Sclerosis)., Journal of Investigative Dermatology, vol.79, issue.s1, pp.87s-89s, 1982.

F. Van-den-hoogen, D. Khanna, J. Fransen, S. R. Johnson, M. Baron et al., 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative, Annals of the Rheumatic Diseases, vol.72, issue.11, pp.1747-1755, 2013.

B. Hervier, M. Rimbert, F. Colonna, M. A. Hamidou, and M. Audrain, Clinical significance of anti-Ro/SSA-52 kDa antibodies--a retrospective monocentric study, Rheumatology, vol.48, issue.8, pp.964-967, 2009.

A. Sánchez-montalvá, A. Fernández-luque, and C. P. Simeón, Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study, Clin Exp Rheumatol, vol.32, pp.177-182, 2014.

A. Lee, A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity, Rheumatology International, vol.37, issue.8, pp.1323-1333, 2017.

A. Menéndez, J. Gómez, E. Escanlar, L. Caminal-montero, and L. Mozo, Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection, Autoimmunity, vol.46, issue.1, pp.32-39, 2012.

M. Hudson, J. Pope, M. Mahler, S. Tatibouet, R. Steele et al., Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis, Arthritis Research & Therapy, vol.14, issue.2, p.R50, 2012.

M. Wodkowski, M. Hudson, S. Proudman, J. Walker, W. Stevens et al., Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects, Autoimmunity, vol.48, issue.8, pp.542-551, 2015.

A. A. Shah and A. Rosen, Cancer and systemic sclerosis, Current Opinion in Rheumatology, vol.23, issue.6, pp.530-535, 2011.

M. Colaci, D. Giuggioli, M. Sebastiani, A. Manfredi, C. Vacchi et al., Lung cancer in scleroderma: Results from an Italian rheumatologic center and review of the literature, Autoimmunity Reviews, vol.12, issue.3, pp.374-379, 2013.

A. Watad, D. Mcgonagle, N. L. Bragazzi, S. Tiosano, D. Comaneshter et al., Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival, OncoImmunology, vol.8, issue.6, p.e1588084, 2019.

S. I. Nihtyanova, A. Sari, J. C. Harvey, A. Leslie, E. C. Derrett?smith et al., Using Autoantibodies and Cutaneous Subset to Develop Outcome?Based Disease Classification in Systemic Sclerosis, Arthritis & Rheumatology, vol.72, issue.3, pp.465-476, 2020.

M. Mahler, M. Hudson, C. Bentow, F. Roup, L. Beretta et al., Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets, Autoimmunity Reviews, vol.19, issue.8, p.102583, 2020.

K. Morrisroe, D. Hansen, M. Huq, W. Stevens, J. Sahhar et al., Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis, Arthritis Care & Research, vol.72, issue.11, pp.1625-1635, 2020.

G. T. Axelsson, R. K. Putman, T. Aspelund, E. F. Gudmundsson, T. Hida et al., The Associations of Interstitial Lung Abnormalities with Cancer Diagnoses and Mortality, European Respiratory Journal, p.1902154, 2020.

S. Shalapour and M. Karin, Immunity, inflammation, and cancer: an eternal fight between good and evil, Journal of Clinical Investigation, vol.125, issue.9, pp.3347-3355, 2015.

S. I. Grivennikov, F. R. Greten, and M. Karin, Immunity, Inflammation, and Cancer, Cell, vol.140, issue.6, pp.883-899, 2010.

Y. Natarajan, A. Tansel, P. Patel, K. Emologu, R. Shukla et al., Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis, Digestive Diseases and Sciences, issue.2, 2020.

O. Hussein, K. Abdelwahab, and O. Hamdy, Thyroid cancer associated with Hashimoto thyroiditis: similarities and differences in an endemic area, J Egypt Natl Canc Inst, vol.32, p.7, 2020.

L. Partouche, R. Goulabchand, A. T. Maria, S. Rivière, C. Jorgensen et al., Biphasic Temporal Relationship between Cancers and Systemic Sclerosis: A Clinical Series from Montpellier University Hospital and Review of the Literature, Journal of Clinical Medicine, vol.9, issue.3, p.853, 2020.

R. D. Schreiber, L. J. Old, and M. J. Smyth, Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.331, issue.6024, pp.1565-1570, 2011.

C. P. Denton and D. Khanna, Systemic sclerosis, The Lancet, vol.390, issue.10103, pp.1685-1699, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02042780

E. C. Leroy, C. Black, R. Fleischmajer, S. Jablonska, T. Krieg et al., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis, J Rheumatol. févr, vol.15, issue.2, pp.202-207, 1988.

S. I. Nihtyanova, A. Sari, J. C. Harvey, A. Leslie, E. C. Derrett?smith et al., Using Autoantibodies and Cutaneous Subset to Develop Outcome?Based Disease Classification in Systemic Sclerosis, Arthritis & Rheumatology, vol.72, issue.3, pp.465-476, 2020.

N. Srivastava, M. Hudson, S. Tatibouet, M. Wang, M. Baron et al., Thinking outside the box?The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect, Seminars in Arthritis and Rheumatism, vol.45, issue.2, pp.184-189, 2015.

C. A. Mecoli and L. Casciola-rosen, An Update on Autoantibodies in Scleroderma, Curr Opin Rheumatol. nov, vol.30, issue.6, pp.548-53, 2018.

R. Aggarwal, M. Lucas, N. Fertig, C. V. Oddis, and T. A. Medsger, Anti-U3 RNP autoantibodies in systemic sclerosis, Arthritis & Rheumatism, vol.60, issue.4, pp.1112-1118, 2009.

A. Sánchez-montalvá, A. Fernández-luque, C. P. Simeón, V. Fonollosa-plà, A. Marín et al.,

-. Anti and . Ssa, Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study, Clin Exp Rheumatol. déc, vol.32, issue.6, pp.177-182, 2014.

A. Lee, A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity, Rheumatol Int. août, vol.37, issue.8, pp.1323-1356, 2017.

A. Menéndez, J. Gómez, E. Escanlar, L. Caminal-montero, and L. Mozo, Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection, Autoimmunity, vol.46, issue.1, pp.32-39, 2012.

S. A. Pendergrass, R. Lemaire, I. P. Francis, J. Matthew-mahoney, R. Lafyatis et al., Intrinsic Gene Expression Subsets of Diffuse Cutaneous Systemic Sclerosis Are Stable in Serial Skin Biopsies, Journal of Investigative Dermatology, vol.132, issue.5, pp.1363-1373, 2012.

M. Elhai, C. Meune, E. Hachulla, A. Balbir-gurman, G. Riemekasten et al., OP0030 Associated Factors with Mortality and Derivation of A Simple 5-Factors To Predict Mortality in Ssc-Patients in The Eustar Cohort, Annals of the Rheumatic Diseases, vol.75, issue.Suppl 2, pp.64.1-64, 2016.

A. J. Tyndall, B. Bannert, M. Vonk, P. Airò, F. Cozzi et al., Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database, Annals of the Rheumatic Diseases, vol.64, issue.7, pp.1107-1107, 2005.

F. Coutant and P. Miossec, Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles, Nature Reviews Rheumatology. déc, vol.12, issue.12, pp.703-718, 2016.

A. Boltjes and F. Van-wijk, Human dendritic cell functional specialization in steady-state and inflammation, Front Immunol, vol.5, p.131, 2014.

T. Carvalheiro, M. Zimmermann, T. Radstake, and W. Marut, Novel insights into dendritic cells in the pathogenesis of systemic sclerosis, Clinical & Experimental Immunology

, Disponible sur

M. D. Ah-kioon, C. Tripodo, D. Fernandez, K. A. Kirou, R. F. Spiera et al., Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8, Sci Transl Med, vol.10, issue.423, 2018.

S. Kafaja, I. Valera, A. A. Divekar, R. Saggar, F. Abtin et al., pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis, JCI Insight, vol.3, issue.9, 2018.

B. Skaug, D. Khanna, W. R. Swindell, M. E. Hinchcliff, T. M. Frech et al., Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile, Ann Rheum Dis. mars, vol.79, issue.3, pp.379-86, 2020.

G. Stifano and R. B. Christmann, Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?, Curr Rheumatol Rep. janv, vol.18, issue.1, p.2, 2016.

C. Frantz, S. Pezet, J. Avouac, and Y. Allanore, OP0095 Soluble cd163 as a potential biomarker in systemic sclerosis, WEDNESDAY, 13 JUNE 2018:, p.8509583, 2018.

C. Chizzolini, N. C. Brembilla, E. Montanari, and M. Truchetet, Fibrosis and immune dysregulation in systemic sclerosis, Autoimmunity Reviews, vol.10, issue.5, pp.276-281, 2011.

M. Hasegawa, K. Takehara, M. Fujimoto, and K. Kikuchi, 022 Serum levels of interleukin-4, interleukin-10, and interleukin-13 in patients with systemic sclerosis, Journal of Dermatological Science, vol.12, issue.2, p.185, 1996.

S. Sato, M. Hasegawa, K. Takehara, S. P. Atamas, R. Wise et al., Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis, Arthritis Rheum. août, vol.27, issue.2, pp.2262-74, 2001.

P. Fuschiotti, A. T. Larregina, J. Ho, C. Feghali-bostwick, and T. A. Medsger, Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis, Arthritis & Rheumatism, vol.65, issue.1, pp.236-246, 2012.

P. Fuschiotti, A. T. Larregina, J. Ho, C. Feghali-bostwick, and T. A. Medsger, Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis, Arthritis & Rheumatism, vol.65, issue.1, pp.236-246, 2012.

S. Sato, M. Fujimoto, M. Hasegawa, and K. Takehara, Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells, Arthritis & Rheumatism, vol.50, issue.6, pp.1918-1927, 2004.

T. Matsushita, Y. Hamaguchi, M. Hasegawa, K. Takehara, and M. Fujimoto, Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity, Rheumatology, vol.55, issue.2, pp.263-267, 2015.

M. Brown and S. O'reilly, The immunopathogenesis of fibrosis in systemic sclerosis, Clinical & Experimental Immunology, vol.195, issue.3, pp.310-331, 2018.

Y. Parel, M. Aurrand-lions, A. Scheja, J. Dayer, E. Roosnek et al., Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis, Arthritis & Rheumatism, vol.56, issue.10, pp.3459-3467, 2007.

H. Hu, D. Chen, Y. Wang, Y. Feng, G. Cao et al., New insights into TGF-?/Smad signaling in tissue fibrosis, Chemico-Biological Interactions, vol.292, pp.76-83, 2018.

T. Mcgaha, S. Saito, R. G. Phelps, R. Gordon, N. Noben-trauth et al., Lack of Skin Fibrosis in Tight Skin (TSK) Mice with Targeted Mutation in the Interleukin-4R? and Transforming Growth Factor-? Genes, Journal of Investigative Dermatology, vol.116, issue.1, pp.136-143, 2001.

S. Bhattacharyya, J. Wei, and J. Varga, Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities, Nature Reviews Rheumatology, vol.8, issue.1, pp.42-54, 2011.

Y. Asano and S. Sato, Vasculopathy in scleroderma, Seminars in Immunopathology, vol.37, issue.5, pp.489-500, 2015.

D. Benedetto, P. Ruscitti, P. Liakouli, V. Cipriani, P. Giacomelli et al., The Vessels Contribute to Fibrosis in Systemic Sclerosis, Isr Med Assoc J. juill, vol.21, issue.7, pp.471-475, 2019.

L. Hui and Y. Chen, Tumor microenvironment: Sanctuary of the devil, Cancer Letters, vol.368, issue.1, pp.7-13, 2015.

T. Frankel, M. P. Lanfranca, and W. Zou, The Role of Tumor Microenvironment in Cancer Immunotherapy, Advances in Experimental Medicine and Biology, pp.51-64, 2017.

R. D. Schreiber, L. J. Old, and M. J. Smyth, Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.331, issue.6024, pp.1565-1570, 2011.

M. W. Teng, J. Galon, W. Fridman, and M. J. Smyth, From mice to humans: developments in cancer immunoediting, Journal of Clinical Investigation, vol.125, issue.9, pp.3338-3346, 2015.

D. Mittal, M. M. Gubin, R. D. Schreiber, and M. J. Smyth, New insights into cancer immunoediting and its three component phases?elimination, equilibrium and escape, Current Opinion in Immunology, vol.27, pp.16-25, 2014.

M. Bitoux and I. Stamenkovic, Tumor-host interactions: the role of inflammation, Histochemistry and Cell Biology, vol.130, issue.6, pp.1079-1090, 2008.

A. K. Rosenthal, J. K. Mclaughlin, G. Gridley, and O. Nyrén, Incidence of cancer among patients with systemic sclerosis, Cancer, vol.76, issue.5, pp.910-914, 1995.

C. Hill, A. Nguyen, D. Roder, and P. Roberts-thomson, Risk of cancer in patients with scleroderma: a population based cohort study, Annals of the Rheumatic Diseases, vol.62, issue.8, pp.728-731, 2003.

S. Chatterjee, G. W. Dombi, R. K. Severson, and M. D. Mayes, Risk of malignancy in scleroderma: A population-based cohort study, Arthritis & Rheumatism, vol.52, issue.8, pp.2415-2424, 2005.

C. T. Derk, C. M. Artlett, and S. A. Jimenez, Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study, Clinical Rheumatology, vol.25, issue.6, pp.831-834, 2006.

J. Zhang, Y. Wan, W. Peng, J. Yan, B. Li et al., The risk of cancer development in systemic sclerosis: A meta-analysis, Cancer Epidemiology, vol.37, issue.5, pp.523-527, 2013.

A. B. Olesen, C. Svaerke, D. K. Farkas, and H. T. Sørensen, Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study, British Journal of Dermatology, vol.163, issue.4, pp.800-806, 2010.

C. Kuo, S. Luo, K. Yu, I. Chou, W. Tseng et al., Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan, Scandinavian Journal of Rheumatology, vol.41, issue.1, pp.44-49, 2011.

A. Onishi, D. Sugiyama, S. Kumagai, and A. Morinobu, Cancer Incidence in Systemic Sclerosis: Meta-Analysis of Population-Based Cohort Studies, Arthritis & Rheumatism, vol.65, issue.7, pp.1913-1921, 2013.

A. Hashimoto, Y. Arinuma, T. Nagai, S. Tanaka, T. Matsui et al., Incidence and the Risk Factor of Malignancy in Japanese Patients with Systemic Sclerosis, Internal Medicine, vol.51, issue.13, pp.1683-1688, 2012.

A. Watad, D. Mcgonagle, N. L. Bragazzi, S. Tiosano, D. Comaneshter et al., Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival, OncoImmunology, vol.8, issue.6, p.e1588084, 2019.

K. Morrisroe, D. Hansen, M. Huq, W. Stevens, J. Sahhar et al., Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis, Arthritis Care & Research, vol.72, issue.11, pp.1625-1635, 2020.

M. Boonstra, T. W. Huizinga, and J. K. De-vries-bouwstra, Auto-antibodies and cancer in systemic sclerosis, Autoimmunity Reviews, vol.16, issue.8, pp.883-884, 2017.

A. A. Shah, L. K. Hummers, L. Casciola-rosen, K. Visvanathan, A. Rosen et al., Examination of Autoantibody Status and Clinical Features Associated With Cancer Risk and Cancer-Associated Scleroderma, Arthritis & Rheumatology, vol.67, issue.4, pp.1053-1061, 2015.

K. Y. Kang, H. W. Yim, I. Kim, J. U. Yoon, J. H. Ju et al., Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre, Scandinavian Journal of Rheumatology, vol.38, issue.4, pp.299-303, 2009.

M. Colaci, D. Giuggioli, M. Sebastiani, A. Manfredi, C. Vacchi et al., Lung cancer in scleroderma: Results from an Italian rheumatologic center and review of the literature, Autoimmunity Reviews, vol.12, issue.3, pp.374-379, 2013.

E. K. Pontifex, C. L. Hill, and P. Roberts-thomson, Risk factors for lung cancer in patients with scleroderma: a nested case-control study, Annals of the Rheumatic Diseases, vol.66, issue.4, pp.551-553, 2006.

P. Moinzadeh, C. Fonseca, M. Hellmich, A. A. Shah, C. Chighizola et al., Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma, Arthritis Research & Therapy, vol.16, issue.1, p.R53, 2014.

T. Igusa, L. K. Hummers, K. Visvanathan, C. Richardson, F. M. Wigley et al., Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer, Annals of the Rheumatic Diseases, p.annrheumdis-2018-212999, 2018.

T. Igusa, L. K. Hummers, K. Visvanathan, C. Richardson, F. M. Wigley et al., Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer, Annals of the Rheumatic Diseases, vol.77, issue.8, p.annrheumdis-2018-212999, 2018.

A. A. Shah, A. Rosen, L. Hummers, F. Wigley, and L. Casciola-rosen, Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies, Arthritis & Rheumatism, vol.62, issue.9, pp.2787-2795, 2010.

P. Airo?, A. Ceribelli, I. Cavazzana, M. Taraborelli, S. Zingarelli et al., Malignancies in Italian Patients with Systemic Sclerosis Positive for Anti-RNA Polymerase III Antibodies, The Journal of Rheumatology, vol.38, issue.7, pp.1329-1334, 2011.

M. Nikpour, P. Hissaria, J. Byron, J. Sahhar, M. Micallef et al., Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis -Saigusa -2015 -The Journal of Dermatology -Wiley Online Library, Arthritis Res Ther, vol.13, issue.6, 2011.

M. G. Lazzaroni, E. Colombo, I. Cavazzana, O. Distler, R. Hesselstrand et al., OP0055 Anti-RNA Polymerase III Antibodies in Patients with Systemic Sclerosis: A Eustar Multicenter Collaborative Study, Annals of the Rheumatic Diseases, vol.74, issue.Suppl 2, pp.88.1-88, 2015.

M. Lazzaroni, I. Cavazzana, E. Colombo, R. Dobrota, J. Hernandez et al., Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening, The Journal of Rheumatology, vol.44, issue.5, pp.639-647, 2017.

D. Bernal-bello, J. G. De-tena, A. Guillén-del-castillo, A. Selva-o'callaghan, E. L. Callejas-moraga et al., Novel risk factors related to cancer in scleroderma, Autoimmunity Reviews, vol.16, issue.5, pp.461-468, 2017.

A. A. Shah, G. Xu, A. Rosen, L. K. Hummers, F. M. Wigley et al., Brief Report: Anti?RNPC?3 Antibodies As a Marker of Cancer?Associated Scleroderma, Arthritis & Rheumatology, vol.69, issue.6, pp.1306-1312, 2017.

A. A. Shah, G. Xu, A. Rosen, L. K. Hummers, F. M. Wigley et al., Brief Report: Anti?RNPC?3 Antibodies As a Marker of Cancer?Associated Scleroderma, Arthritis & Rheumatology, vol.69, issue.6, pp.1306-1312, 2017.

S. Vettori, S. Staibano, M. Mascolo, G. Ilardi, and G. Valentini, Non-Hodgkin?s lymphoma in systemic sclerosis: case and literature review, Clinical Rheumatology, vol.29, issue.1, pp.1-6, 2009.

A. A. Shah and L. Casciola-rosen, Cancer and scleroderma, Current Opinion in Rheumatology, vol.27, issue.6, pp.563-570, 2015.

A. A. Shah and L. Casciola-rosen, Mechanistic and clinical insights at the scleroderma-cancer interface, Journal of Scleroderma and Related Disorders, vol.2, issue.3, pp.153-159, 2017.

A. T. Maria, L. Partouche, R. Goulabchand, S. Rivière, P. Rozier et al., Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors, Frontiers in Immunology, vol.9, issue.2019, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02307243

M. Dolcino, A. Pelosi, P. F. Fiore, G. Patuzzo, E. Tinazzi et al., Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures, Frontiers in Immunology, vol.9, p.449, 2018.

P. Boffetta and D. Hashim, Exposure to silicon carbide and cancer risk: a systematic review, International Archives of Occupational and Environmental Health, vol.90, issue.1, pp.1-12, 2016.

I. Marie, J. Gehanno, M. Bubenheim, A. Duval-modeste, P. Joly et al., Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature, Autoimmunity Reviews, vol.13, issue.2, pp.151-156, 2014.

M. Pesic and F. R. Greten, Inflammation and cancer: tissue regeneration gone awry, Current Opinion in Cell Biology, vol.43, pp.55-61, 2016.

L. B. Travis, R. E. Curtis, B. Glimelius, E. J. Holowaty, F. E. Van-leeuwen et al., Bladder and Kidney Cancer Following Cyclophosphamide Therapy for Non-Hodgkin's Lymphoma, JNCI Journal of the National Cancer Institute, vol.87, issue.7, pp.524-531, 1995.

C. Talar-williams, Y. M. Hijazi, M. M. Walther, W. M. Linehan, C. W. Hallahan et al.,

C. Talar-williams, Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis, Annals of Internal Medicine, vol.124, issue.5, p.477, 1996.

A. Gulamhusein and J. E. Pope, Squamous Cell Carcinomas in 2 Patients with Diffuse Scleroderma Treated with Mycophenolate Mofetil, The Journal of Rheumatology, vol.36, issue.2, pp.460-461, 2009.

C. I. Li, J. R. Daling, M. Tang, K. L. Haugen, P. L. Porter et al., Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years, JAMA Internal Medicine, vol.173, issue.17, p.1629, 2013.

A. L. Fitzpatrick, J. R. Daling, C. D. Furberg, R. A. Kronmal, and J. L. Weissfeld, Use of calcium channel blockers and breast carcinoma risk in postmenopausal women, Cancer, vol.80, issue.8, pp.1438-1447, 1997.

C. G. Joseph, E. Darrah, A. A. Shah, A. D. Skora, L. A. Casciola-rosen et al., Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer, Science, vol.343, issue.6167, pp.152-157, 2013.

C. Bruni, A. Lages, H. Patel, S. I. Nihtyanova, B. Green et al., Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour, Rheumatology, vol.56, issue.2, pp.317-318, 2016.

M. Juarez, R. Marshall, C. Denton, and R. Evely, Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine, Rheumatology, vol.47, issue.11, pp.1734-1735, 2008.

C. Atalay, L. Dogan, and G. Atalay, Anti-CENP-B antibodies are associated with prolonged survival in breast cancer, Future Oncology, vol.6, issue.3, pp.471-477, 2010.

A. A. Shah, L. K. Hummers, L. Casciola-rosen, K. Visvanathan, A. Rosen et al., Examination of Autoantibody Status and Clinical Features Associated With Cancer Risk and Cancer-Associated Scleroderma, Arthritis & Rheumatology, vol.67, issue.4, pp.1053-1061, 2015.

C. C. Berger, C. Bokemeyer, M. Schneider, M. A. Kuczyk, and H. Schmoll, Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer, European Journal of Cancer, vol.31, issue.13-14, pp.2229-2238, 1995.

T. Shimura, N. Fuse, T. Yoshino, K. Minashi, M. Tahara et al., Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer, Annals of Oncology, vol.21, issue.10, pp.2005-2010, 2010.

D. Bessis, B. Guillot, E. Legouffe, and J. Guilhou, Gemcitabine-associated scleroderma-like changes of the lower extremities, Journal of the American Academy of Dermatology, vol.51, issue.2, pp.73-76, 2004.

B. Park, R. C. Vemulapalli, A. Gupta, M. E. Shreve, and D. A. Rees, Docetaxel-Induced Systemic Sclerosis with Internal Organ Involvement Masquerading as Congestive Heart Failure, Case Reports in Immunology, vol.2017, pp.1-3, 2017.

A. Moeller, K. Ask, D. Warburton, J. Gauldie, and M. Kolb, The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?, The International Journal of Biochemistry & Cell Biology, vol.40, issue.3, pp.362-382, 2008.

A. Alhathlool, R. Hein, C. Andres, J. Ring, and B. Eberlein, Post-Irradiation Morphea: Case report and review of the literature, Journal of Dermatological Case Reports, vol.6, issue.3, pp.73-80, 2012.

D. Wechsler, B. Blétry, O. Piette, and J. C. , De novo systemic sclerosis after radiotherapy: a report of 3 cases, J Rheumatol, vol.26, issue.10, pp.2265-2272, 1999.

M. Kostine, L. Rouxel, T. Barnetche, R. Veillon, F. Martin et al., Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer?clinical aspects and relationship with tumour response: a single-centre prospective cohort study, Annals of the Rheumatic Diseases, vol.77, issue.3, pp.393-398, 2017.

D. Benfaremo, L. Manfredi, M. M. Luchetti, and A. Gabrielli, Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature, Current Drug Safety, vol.13, issue.3, pp.150-164, 2018.

N. S. Barbosa, D. A. Wetter, C. N. Wieland, N. K. Shenoy, S. N. Markovic et al., Scleroderma Induced by Pembrolizumab: A Case Series, Mayo Clinic Proceedings, vol.92, issue.7, pp.1158-1163, 2017.

M. Cho, Y. Nonomura, Y. Kaku, S. Nakabo, Y. Endo et al., Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma, The Journal of Dermatology, vol.46, issue.1, pp.e43-e44, 2018.

M. R. Moro and J. Brison, Vouloir le bien-être et la santé de tous à l?école, La Revue de Santé Scolaire et Universitaire, vol.8, issue.45, pp.11-18, 2017.

. Prâevost, Â. M. Chomprâe, A. Deleyre, J. Green, A. Meusnier-de-querlon et al., Histoire gâenâerale des voyages, ou, Nouvelle collection de toutes les relations de voyages par mer et par terre, qui ont âetâe publiâees jusqu'áa present dans les diffâerentes langues de toutes les nations connues : contenant ce qu'il y a de plus remarquable, de plus utile et de mieux averâe dans les pays ou les voyageurs ont penetrâe : touchant leur situation, leur âetendue, leurs limites, leurs divisions, leur climat, leur terroir, leurs productions, leurs lacs, leurs rivieres, leurs montagnes, leurs mines, leurs citâes & leurs principales villes, leurs ports, leurs rades, leurs edifices, &c. : avec les moeurs et les usages des habitans, leur religion, leur gouvernement, leurs arts et leurs sciences, leur commerce et leurs manufactures : pour former un systâeme complet d'histoire et de gâeographie moderne, qui representera l'âetat actuel de toutes les nations : enrichi de cartes gâeographiques nouvellement composâees sur les observations les plus autentiques :, 1746.

. Prâevost, Â. M. Chomprâe, A. Deleyre, J. Green, A. Meusnier-de-querlon et al., Histoire gâenâerale des voyages, ou, Nouvelle collection de toutes les relations de voyages par mer et par terre, qui ont âetâe publiâees jusqu'áa present dans les diffâerentes langues de toutes les nations connues : contenant ce qu'il y a de plus remarquable, de plus utile et de mieux averâe dans les pays ou les voyageurs ont penetrâe : touchant leur situation, leur âetendue, leurs limites, leurs divisions, leur climat, leur terroir, leurs productions, leurs lacs, leurs rivieres, leurs montagnes, leurs mines, leurs citâes & leurs principales villes, leurs ports, leurs rades, leurs edifices, &c. : avec les moeurs et les usages des habitans, leur religion, leur gouvernement, leurs arts et leurs sciences, leur commerce et leurs manufactures : pour former un systâeme complet d'histoire et de gâeographie moderne, qui representera l'âetat actuel de toutes les nations : enrichi de cartes gâeographiques nouvellement composâees sur les observations les plus autentiques :, 1746.

, Graphique 10.7. Les migrants très instruits ne sont pas les plus enclins à regagner leur pays d'origine, et ce pour la plupart des pays

, Comment puis-je me tenir informé des technologies les plus récentes, des nouveaux modèles de fabrication, et de la recherche-développement?, 2003.

C. Cassiau-haurie, Lazhari Labter :« Je publie des livres qui me parlent et dont le contenu interpelle les lecteurs sur des questions qui agitent nos sociétés », Africultures, vol.84, issue.2, p.24, 2011.

, II. Überwachung der Feuerung. Furnace Control. Contrôle des foyers, Conduite et contrôle des chaudières. Abaques pour les ingénieurs et techniciens des industries thermique, pp.34-53, 1936.

M. Sandras, « Je ne suis pas un écrivain, je suis le poète qui chante » Les entretiens de Paul Fort avec Michel Manoll, Écrivains au micro, pp.201-15

W. Coolsaet, "Je speelt, je wint. Je verliest. Je speelt" Reflecties bij Jeanette Winterson, De passie, De Uil van Minerva, vol.21, issue.2-3, 2006.

A. Niess, Conclusion. Le spectre des deux-cents familles ?, L?hérédité en République, pp.327-328, 2012.

, Si je constate une violation de mes droits de propriété intellectuelle, que dois-je ou que puis-je faire?, 2004.